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BIVENTRICULAR PACING
AFTER CARDIAC SURGERY
To the Editor:
We read with interest the article by
Evonich and colleagues1 in the Octo-
ber issue of the Journal. They per-
formed a randomized study of pacing
modes (‘‘normal care,’’ synchronous
atrial-right ventricular pacing, and
synchronous atrial–biventricular pac-
ing) in 40 patients with impaired left
ventricular function after cardiac sur-
gery. They included both a crossover
study of acute hemodynamic variables
early after operation (in 29 patients)
and an assessment of clinical end
points, such as intensive therapy unit
and hospital stay andmortality. In con-
trast with experience in chronic heart
failure, they showed no advantage to
biventricular pacing in any area, al-
though the trial was underpowered
for the clinical end points.
They suggest this was the first ran-
domized study in surgical patients but
did not cite our 2005 publication.2
We performed a similar randomized
crossover study, with hemodynamic
assessment of different pacing modes
in a similar number of patients (25)
early after surgery. We demonstrated
a clear advantage to atrial–left ventric-
ular pacing and regard this modality as
an important addition to the postopera-
tive care of the compromised patient.
Closer analysis of the results in the
article by Evonich and colleagues1
suggests that there is a serious error
or that they too found an advantage
but did not recognize it. In the second
paragraph of the section titled ‘‘Hemo-
dynamic Testing,’’ they state a statisti-
cally significant difference in stroke
volume, cardiac output, and left ven-
tricular stroke work index between
AAI and atrial-right ventricular pacing.
But, in Table 2, the values they refer to
in the text are in the column under
atrial–biventricular pacing pacing. If
Table 2 is to be believed (and there is
inconsistency in nomenclature, does
AAI equate to ‘‘usual care’’?), these
investigators did see an advantage to
biventricular pacing.
We believe biventricular pacing is
of advantage to the postsurgical pa-
tient. Even if we are mistaken in our
interpretation of this article, surgeons
are left with 2 series of patients with
contrasting results, perhaps because
both have small numbers. This calls
for a larger definitive study.
Michael Flynn, FRCS
John H. Dark, FRCS
Janet M. McComb, FRCP, MD
University of Newcastle upon Tyne
United Kingdom
Letters to the EditorLATE RUPTURE OF EXPANDED
POLYTETRAFLUORO-
ETHYLENE NEOCHORDAE
USED FOR MITRALVALVE
REPAIR
To the Editor:
In the February issue of the Journal,
Farivar and colleagues1 described
a case of late rupture of expanded
polytetrafluoroethylene (ePTFE) neo-
chordae after mitral valve repair. In the
‘‘Discussion,’’ they state that there
was only 1 previous case reported in
the literature of ruptured neochordae,
presented by Buttany and colleagues,2
suggesting their case as the second re-
ported. This is not correct. In 2007, the
Journal of Heart Valve Disease pub-
lished our report of 2 cases of acute mi-
tral regurgitation caused by ruptured
ePTFE neochordae.3 Our patients pre-
sented with symptoms of acute heart
failure caused by sudden rupture of the
chordae, which was different from the
rare clinical manifestations, hemolysis,
and hematuria experienced by the pa-
tient reportedbyFarivar and colleagues.
We first used ePTFE routinely to
correct ruptured or elongated chordae
tendineae during the late 1980s and
have since implanted it in more than
500 patients without a single known
case of ePTFE failure necessitating re-
operation, until these 2 late events oc-
curred. After a thorough literatureThe Journasearch regarding the possible mecha-
nisms behind this unusual occurrence,
we analyzed our histopathologic find-
ings. We found that there was likely
pannus formation and collagen infil-
tration through the porous structure
that could account for progressive dis-
ruption before calcification ensued,
which could be postulated as a form
of repair/scarring.
In addition to the degenerative
causes that could be responsible for
the late rupture, we believe that the
use of forceps and other metal instru-
ments in the manipulation of the
ePTFE could interrupt its electronega-
tive charge and weaken the material.
We currently avoid any kind of metal-
lic manipulation.
Gonc¸alo Coutinho, MD
Lina Carvalho, MD, PhD
Manuel J. Antunes, MD, PhD, DSc
Center of Cardiothoracic Surgery
University Hospital
Coimbra, Portugal
References
1. Farivar RS, Shernan SK, Cohn LH. Late rupture of
polytetrafluoroethylene neochordae after mitral
valve repair. J Thorac Cardiovasc Surg. 2009;
137:504-6.
2. Buttany J, Collins MJ, David TE. Ruptured syn-
thetic expanded polytetrafluoroethylene chordae
tendineae. Cardiovasc Pathol. 2004;13:182-4.
3. Coutinho GF, Carvalho L, Antunes MJ. Acute mi-
tral regurgitation due to ruptured ePTFE neo-chor-
dae. J Heart Valve Dis. 2007;16:278-81.
doi:10.1016/j.jtcvs.2009.02.050l of Thoracic and Cardiovascular Surgery c Volume 138, Number 1 259
